Trial Profile

The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asunercept (Primary)
Indications Glioblastoma
Focus Biomarker; Pharmacodynamics
Sponsors CANbridge Pharmaceuticals

Most Recent Events

26 Aug 2019 According to the CANbridge Pharmaceuticals website, the company was formerly called as CANbridge Life Sciences.
21 Sep 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.
21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com